[
    [
        {
            "time": "",
            "original_text": "沃森生物第三季度净利润同比下滑逾8成 mRNA疫苗商业化进程最关注 盈利能力下降",
            "features": {
                "keywords": [
                    "沃森生物",
                    "第三季度",
                    "净利润",
                    "下滑",
                    "mRNA疫苗",
                    "商业化",
                    "盈利能力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沃森生物第三季度净利润同比下滑逾8成 mRNA疫苗商业化进程最关注 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "沃森生物，深不见底?",
            "features": {
                "keywords": [
                    "沃森生物",
                    "深不见底"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沃森生物，深不见底?",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "国产新冠疫苗迎“收获期”，龙头企业第三季度业绩暴涨",
            "features": {
                "keywords": [
                    "国产",
                    "新冠疫苗",
                    "收获期",
                    "龙头企业",
                    "第三季度",
                    "业绩",
                    "暴涨"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国产新冠疫苗迎“收获期”，龙头企业第三季度业绩暴涨",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "沃森生物跌4.96% 中信证券上月初喊买入",
            "features": {
                "keywords": [
                    "沃森生物",
                    "跌",
                    "中信证券",
                    "买入"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沃森生物跌4.96% 中信证券上月初喊买入",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "沃森生物(300142.SZ)半日收跌4.27% Q3净利润同比下降87.92% 盈利能力下降",
            "features": {
                "keywords": [
                    "沃森生物",
                    "收跌",
                    "Q3",
                    "净利润",
                    "下降",
                    "盈利能力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "沃森生物(300142.SZ)半日收跌4.27% Q3净利润同比下降87.92% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "新疫苗获批叠加业绩增长130% 康泰生物股价为何开启“下跌模式”",
            "features": {
                "keywords": [
                    "新疫苗",
                    "获批",
                    "业绩增长",
                    "康泰生物",
                    "股价",
                    "下跌模式"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "新疫苗获批叠加业绩增长130% 康泰生物股价为何开启“下跌模式”",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中信建投医药大健康团队最新研究",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药",
                    "大健康",
                    "研究"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中信建投医药大健康团队最新研究",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "HPV疫苗一针难求，国内已有16款在研",
            "features": {
                "keywords": [
                    "HPV疫苗",
                    "一针难求",
                    "国内",
                    "在研"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "HPV疫苗一针难求，国内已有16款在研",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]